SG11202112980TA - Targeted protein degradation of parp14 for use in therapy - Google Patents
Targeted protein degradation of parp14 for use in therapyInfo
- Publication number
- SG11202112980TA SG11202112980TA SG11202112980TA SG11202112980TA SG11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA SG 11202112980T A SG11202112980T A SG 11202112980TA
- Authority
- SG
- Singapore
- Prior art keywords
- parp14
- therapy
- protein degradation
- targeted protein
- targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962863357P | 2019-06-19 | 2019-06-19 | |
| PCT/US2020/038377 WO2020257416A1 (en) | 2019-06-19 | 2020-06-18 | Targeted protein degradation of parp14 for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112980TA true SG11202112980TA (en) | 2021-12-30 |
Family
ID=71527971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112980TA SG11202112980TA (en) | 2019-06-19 | 2020-06-18 | Targeted protein degradation of parp14 for use in therapy |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220388985A1 (en) |
| EP (1) | EP3986887A1 (en) |
| JP (1) | JP2022537349A (en) |
| KR (1) | KR20220024098A (en) |
| CN (1) | CN114206853A (en) |
| AU (1) | AU2020296063A1 (en) |
| BR (1) | BR112021025645A2 (en) |
| CA (1) | CA3142002A1 (en) |
| MA (1) | MA56513A (en) |
| SG (1) | SG11202112980TA (en) |
| WO (1) | WO2020257416A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111699176A (en) | 2017-12-21 | 2020-09-22 | 里邦医疗公司 | Quinazolinones as PARP14 inhibitors |
| KR20230144008A (en) * | 2021-01-08 | 2023-10-13 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Nimbolide analogues and methods of use thereof |
| EP4284376A1 (en) * | 2021-01-29 | 2023-12-06 | Ribon Therapeutics Inc. | Methods of treating inflammatory diseases |
| CN114890989B (en) * | 2022-05-25 | 2024-03-22 | 广东晨康生物科技有限公司 | HDAC8 degradation agent with nitrogenous derivative as Linker, preparation method and application thereof |
| WO2024026081A1 (en) | 2022-07-29 | 2024-02-01 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| WO2024026083A1 (en) | 2022-07-29 | 2024-02-01 | Ribon Therapeutics, Inc. | Targeted protein degradation of parp14 for use in therapy |
| CN117658983A (en) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | Selective PARP1 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY180775A (en) * | 2014-04-23 | 2020-12-09 | Incyte Corp | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| US20210154184A1 (en) * | 2017-07-12 | 2021-05-27 | Dana-Farber Cancer Institute, Inc. | Compounds for tau protein degradation |
-
2020
- 2020-06-18 JP JP2021575326A patent/JP2022537349A/en active Pending
- 2020-06-18 CA CA3142002A patent/CA3142002A1/en active Pending
- 2020-06-18 BR BR112021025645A patent/BR112021025645A2/en unknown
- 2020-06-18 KR KR1020217041538A patent/KR20220024098A/en unknown
- 2020-06-18 EP EP20737701.1A patent/EP3986887A1/en active Pending
- 2020-06-18 WO PCT/US2020/038377 patent/WO2020257416A1/en unknown
- 2020-06-18 MA MA056513A patent/MA56513A/en unknown
- 2020-06-18 CN CN202080044704.2A patent/CN114206853A/en active Pending
- 2020-06-18 AU AU2020296063A patent/AU2020296063A1/en active Pending
- 2020-06-18 SG SG11202112980TA patent/SG11202112980TA/en unknown
- 2020-06-18 US US17/619,459 patent/US20220388985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021025645A2 (en) | 2022-02-01 |
| AU2020296063A1 (en) | 2021-12-23 |
| CN114206853A (en) | 2022-03-18 |
| JP2022537349A (en) | 2022-08-25 |
| CA3142002A1 (en) | 2020-12-24 |
| US20220388985A1 (en) | 2022-12-08 |
| EP3986887A1 (en) | 2022-04-27 |
| KR20220024098A (en) | 2022-03-03 |
| WO2020257416A1 (en) | 2020-12-24 |
| MA56513A (en) | 2022-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202112980TA (en) | Targeted protein degradation of parp14 for use in therapy | |
| IL276464A (en) | Methods and compositions for therapeutic protein delivery | |
| EP3621648A4 (en) | Msln targeting trispecific proteins and methods of use | |
| IL260222A (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| IL287082A (en) | Methods and compositions for targeted protein degradation | |
| IL292810A (en) | Therapeutic compounds and methods of use | |
| MX2023008211A (en) | Compositions and methods for decreasing tau expression. | |
| HUE058289T2 (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
| HK1232242A1 (en) | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| IL288728A (en) | Anti-sortilin antibodies for use in therapy | |
| EP4013445A4 (en) | Therapeutic protein compositions and methods | |
| IL271327A (en) | Compositions and methods for enhancing hyperthermia therapy | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL283687A (en) | Usp19 inhibitors for use in therapy | |
| EP3886913A4 (en) | Enhanced targeted delivery of therapeutic agents | |
| GB201812861D0 (en) | Methods of administering therapy | |
| EP3965793C0 (en) | Peptides for use in therapy or prophylaxis of herpesviridae-infections | |
| AU2019903877A0 (en) | Inhibitors of protein kinases for use in therapy | |
| GB201913114D0 (en) | Targeted sequencing of y-chromosome | |
| ZA202106250B (en) | Therapeutic uses of dulaglutide | |
| IL287923B1 (en) | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating luts | |
| EP3713589A4 (en) | Apratyramide therapeutic agents and methods of treatment | |
| EP3624852A4 (en) | Inducing phospholipidosis for enhancing therapeutic efficacy | |
| EP3579886A4 (en) | Method of use for therapeutic bone agents |